FDG PET/CT for tumoral and systemic immune response monitoring of advanced melanoma during first-line combination ipilimumab and nivolumab treatment
Amir Iravani, Medhat M Osman, Alison M Weppler, Roslyn Wallace, Anna Galligan, Arian Lasocki, Morgan O Hunter, Tim Akhurst, Michael S Hofman, Peter KH Lau, Damien Kee, George Au-Yeung, Shahneen Sandhu, Rodney J Hicks
European Journal of Nuclear Medicine and Molecular Imaging | SPRINGER | Published : 2020
PURPOSE: We aimed to investigate the role of FDG-PET/CT in monitoring of response and immune-related adverse events (irAEs) following first-line combination-immune checkpoint inhibitor (combination-ICI) therapy for advanced melanoma. METHODS: We retrospectively reviewed outcomes in patients who had (1) first-line nivolumab plus ipilimumab; (2) pre- and post-treatment FDG-PET/CT scans (pre-FDG-PET/CT and post-FDG-PET/CT) within 2 and 4 months of starting ICI, respectively; and (3) at least one lesion assessable by PET response criteria in solid tumors (PERCIST). Extracranial response was monitored by 3 monthly FDG-PET/CT. Whole-body metabolic tumor volume (wbMTV) was measured pre- and post-tr..View full abstract
This research was partially supported by the Victorian Cancer Agency.